The Sixth Circuit Court of Appeals recently upheld the sentences of Reina Chirinos de Urena and Michael Basalyga for their involvement in a large-scale drug operation that sold counterfeit Xanax pills on the dark web. The court ruled on October 19, 2026, affirming Chirinos de Urena's 45-month prison sentence and Basalyga's 80-month sentence. This decision is significant as it reinforces the legal consequences for those involved in drug counterfeiting, a crime that poses serious risks to public health.
Chirinos de Urena and Basalyga were part of a conspiracy that produced and sold millions of fake generic Xanax pills, which are used to treat anxiety. The operation was discovered by federal investigators, leading to charges against multiple participants, including the duo and their co-conspirator, Omar Wala. All three pleaded guilty to conspiracy and substantive counterfeiting of drugs. The case highlights the ongoing battle against drug-related crimes and the importance of strict sentencing to deter similar offenses.
The appeal arose after both defendants challenged various aspects of their sentences, including the calculation of their prison terms based on the U.S. Sentencing Guidelines. The district court had initially set a high sentencing range for both defendants due to the severity of their crimes, but ultimately imposed sentences below the guidelines. Basalyga received an 80-month sentence, while Chirinos de Urena was sentenced to 45 months. Their appeals were based on claims of procedural errors in how their sentences were determined.
In its ruling, the court noted that both defendants had waived their right to contest certain aspects of their sentences by agreeing to the terms of their plea deals. The court stated, "Because Basalyga asked the district court to use the 1988 version of the Guidelines and did not object to using that version below, he forfeited any right he might have had to being sentenced under the newer Guidelines." This waiver played a crucial role in the court's decision, as it limited the grounds for their appeal.
The court also addressed the defendants' arguments regarding the calculation of losses associated with their counterfeit drug sales. The sentencing guidelines allow for enhancements based on the amount of loss caused by the crime. The district court calculated the loss at approximately $32.2 million, which significantly influenced the sentencing enhancements applied to Basalyga. The court affirmed that the district court's approach to calculating loss was appropriate and consistent with previous rulings.
Chirinos de Urena's appeal included a challenge to a two-level enhancement for the risk of death or serious bodily injury associated with the counterfeit drugs. The court found that the nature of the operation presented significant risks to consumers, who unknowingly purchased potentially dangerous substances. The court stated, "The scheme involved millions of 'crudely' manufactured pills being funneled into an 'unregulated' and unsupervised market," reinforcing the seriousness of their actions.
The court's ruling has broader implications for future cases involving drug counterfeiting and the enforcement of sentencing guidelines. This case serves as a reminder of the legal consequences that individuals can face when engaging in drug-related crimes, especially those that endanger public health. The decision may also set a precedent for how courts handle similar cases in the future, particularly regarding the calculation of losses and the application of sentencing enhancements.
Looking ahead, it is unclear whether the defendants will seek further appeals. However, given the court's firm stance on the issues raised, it appears challenging to overturn the ruling. The case underscores the importance of adhering to sentencing guidelines and the potential repercussions for those involved in drug counterfeiting operations.